LENZLENZ Therapeutics Inc. Common Stock

Prescription growth surged 45% in July after telehealth launch.

The analyst fair value estimate for LENZ Therapeutics has shifted from US$32.00 to about US$26.83 per share, which now lines up more closely with the US$7 price target cluster that many firms reference. This reset reflects the more cautious stance in recent research, where several analysts cut price targets and moved to Neutral while they reassess the VIZZ launch and the company’s cash support. As you read on, you will see how these moving targets shape the evolving LENZ Therapeutics...

Strong cash position and expanding global partnerships offset modest Q2 product revenue growth as the company scales commercial execution.

Moby summary of LENZ Therapeutics, Inc.'s Q2 2026 earnings call

LENZ Therapeutics (NASDAQ:LENZ) reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity following the July rollout of national television advertising and a telehealth access option. Product r

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of +15.70% and +148.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -28.57% and -59.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LENZ Therapeutics, Inc. (LENZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.